SCHEMBL26032430

SCHEMBL26032430

CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](OC(=O)NCCOCCNC(=O)OC(C)(C)C)CC[C@]4(C)[C@H]3CC[C@]12C

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ POLA1 P09884 1/20 0.64
▸ CYP46A1 Q9Y6A2 2/20 0.63
▸ USP2 O75604 2/20 0.59
▸ OSBP P22059 2/20 0.59
▸ RORC P51449 2/20 0.59
▸ OSBP2 Q969R2 2/20 0.59
▸ LMNA P02545 1/20 0.59
▸ ABCB1 P08183 1/20 0.59
▸ NR1H3 Q13133 3/20 0.57
▸ NPC1L1 Q9UHC9 5/20 0.56
▸ GBA1 P04062 2/20 0.53
▸ UGCG Q16739 2/20 0.53
▸ GBA2 Q9HCG7 2/20 0.53
▸ PLA2G2A P14555 1/20 0.53
▸ CRYAB P02511 1/20 0.53
▸ HMGCR P04035 1/20 0.53
▸ ITGB3 P05106 1/20 0.53
▸ ITGAV P06756 1/20 0.53
▸ SREBF2 Q12772 1/20 0.53
▸ NPC1 O15118 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25835344 1.00 POLA1 (0.64) POLA1CYP46A1USP2OSBPRORC
SCHEMBL15702072 0.99 POLA1 (0.63) POLA1CYP46A1USP2OSBPRORC
SCHEMBL17665326 0.99 POLA1 (0.63) POLA1CYP46A1USP2OSBPRORC
SCHEMBL26032472 0.99 POLA1 (0.63) POLA1CYP46A1USP2OSBPRORC
SCHEMBL26041071 0.97 POLA1 (0.60) POLA1CYP46A1USP2OSBPRORC
SCHEMBL24341653 0.96 POLA1 (0.68) POLA1CYP46A1USP2OSBPRORC
SCHEMBL25835317 0.96 POLA1 (0.68) POLA1CYP46A1USP2OSBPRORC
SCHEMBL26172664 0.95 POLA1 (0.67) POLA1CYP46A1USP2OSBPRORC
SCHEMBL15686572 0.94 CYP46A1 (0.67) POLA1CYP46A1USP2OSBPRORC
SCHEMBL30390458 0.94 CYP46A1 (0.67) POLA1CYP46A1USP2OSBPRORC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230265429-A1 SKELETAL MUSCLE DELIVERY PLATFORMS AND METHODS OF USE THEREOF Arrowhead Pharmaceuticals, Inc. 2023-08-24 — — US disclosed
US-20230265429-A1 SKELETAL MUSCLE DELIVERY PLATFORMS AND METHODS OF USE THEREOF Arrowhead Pharmaceuticals, Inc. 2023-08-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230265429-A1 SKELETAL MUSCLE DELIVERY PLATFORMS AND METHODS OF USE THEREOF MUSK, MYLK2, TNNC1 POLA1 2871/4885CYP46A1 4314/4885USP2 2938/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback